



JPW

ATTORNEY DOCKET NO. 2004993-0011 (VPI/03-101 US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Maltais *et al.* Examiner: Not yet assigned
Serial No.: 10/798,766 Art Unit: 1614
Filed: March 11, 2004 Confirmation No.: 8361
Title: COMPOSITIONS USEFUL AS PROTEIN KINASE INHIBITORS

Mail Stop: Amendments
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

Enclosed are the following documents:

1. Form PTO-1449 (1 page);
2. Information Disclosure Statement (6 pages);
3. Transmittal Letter (1 page)
4. Cited Art (11); and
5. Return Postcard.

If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721.

Respectfully submitted,

Andrea L. C. Robidoux, Reg. No. 47,902
Agent for Applicants

Choate, Hall & Stewart
Exchange Place
53 State Street
Boston, MA 02109
(617) 248-5000
(617) 248-4000

Dated: 1/13/05
3788996

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop: Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

1-13-05
Date

Sandra Saccoccia
Signature

Sandra Saccoccia

Typed or Printed Name of person signing certificate



ATTORNEY DOCKET NO. 2004993-0011 (VPI/03-101 US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Maltais <i>et al.</i>	Examiner:	Not yet assigned
Serial No.:	10/798,766	Art Unit:	1614
Filed:	March 11, 2004	Confirmation No.:	8361
Title:	COMPOSITIONS USEFUL AS PROTEIN KINASE INHIBITORS		

Mail Stop: Amendments
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT UNDER 37 C.F.R. §§ 1.56, 1.97, & 1.98

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:

- ☒ [X] An *original* Information Disclosure Statement; or
- ☐ [] A *supplemental* Information Disclosure Statement.

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop: Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

1-13-05 *Sandra Saccoccia*

Date

Signature

Sandra Saccoccia

Typed or Printed Name of person signing certificate

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

- ☒ Pursuant to 37 CFR § 1.97(b); no fee or certification is required:
 - ☐ Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);
 - ☐ Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;
 - ☒ Before the mailing of a first Office action on the merits; or
 - ☐ Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.
- ☐ Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *either*:
 - ☐ Certifies that *either*:
 - ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
 - ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the

knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; or

☐ Includes herewith the fee set forth in § 1.17(p). Please charge Deposit Account No. 03-1721.

☐ Pursuant to 37 CFR § 1.97(d), after the mailing date of any final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *both*:

☐ Certifies that *either*:

☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; and

☐ Includes herewith the fee set forth in § 1.17(p).

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

☒ A copy of each cited reference not indicated with an asterisk is included;

☐ Copies of references indicated with an asterisk on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously provided to the United States Patent Office in an Information Disclosure Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status

☐ Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement *either*:

☒ Does not contain non-English language citations;

☐ Does contain non-English language citations, for which an English language abstract is submitted.

[] Does contain non-English language citations which were cited on an International Search Report (a copy of which is enclosed herewith).

[] Includes one or more translations of a non-English citation.

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b) .


The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,



Andrea L. C. Robidoux, Reg. No. 47,902
Agent for Applicants

CHOATE, HALL & STEWART
Exchange Place
53 State Street
Boston, Massachusetts 02109
(617) 248-5000
(617) 248-4000

Date:



3788990

Form PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket: 2004993-0011 (VPI/03-101 US)		In re Application No. 10/798,766	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant: Maltais <i>et al.</i>			
				Filing Date: March 11, 2004		Group:	
U.S. PATENT DOCUMENTS							
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date		Class	Subclass	
U.S. PATENT APPLICATIONS							
Examiner's Initials:	Publication Number:	Applicant:	Publication Date:		Group:	Art Unit:	
FOREIGN PATENT DOCUMENTS							
Examiner's Initials	Document No.	Country	Date	Translation			
				Yes	No		
OTHER DOCUMENTS							
Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)						
	Brownlees, et al., "Tau Phosphorylation in Transgenic Mice Expressing Glycogen Synthase Kinase-3 β Transgene", <i>NeuroReport</i> , 8 : 3251-3255, 1997.						
	Carmichael, et al., "Glycogen Synthase Kinase-3 β Inhibitors Prevent Cellular Polyglutamine Toxicity Caused by the Huntington's Disease Mutation", <i>The Journal of Biological Chemistry</i> , 277 (37): 33791-33798, 2002.						
	Cohen, et al., "The Renaissance of GSK3", <i>Molecular Cell Biology</i> , 2 : 769-776, 2001.						
	Cohen, et al., "Dissection of the Protein Phosphorylation Cascades Involved in Insulin and Growth Factor Action", <i>Twenty-Fourth Ciba Medal Lecture</i> , 21 : 555-567, 1993.						
	Cross, et al., "The Inhibition of Glycogen Synthase Kinase-3 by Insulin or Insulin-Like Growth Factor 1 in the Rat Skeletal Muscle Cell Line L6 is Blocked by Wortmannin, But Not by Rapamycin: Evidence that Wortmannin Blocks Activation of the Mitogen-Activated Protein Kinase Pathway in L6 Cells Between Ras and Raf", <i>Biochem. J.</i> 303 : 21-26, 1994.						
	Fabbro, et al., "Protein Kinases as Targets for Anticancer Agents: From Inhibitors to Useful Drugs", <i>Pharmacology & Therapeutics</i> , 93 : 79-98, 2002.						
	Kaytor, et al., "The GSK3 β Signaling Cascade and Neurodegenerative Disease", <i>Current Opinion in Neurobiology</i> , 12 : 275-278, 2002.						
	Klein, et al., "A Molecular Mechanism for the Effect of Lithium on Development", <i>Proc. Natl. Acad. Sci. USA</i> , 93 : 8455-8459, 1996.						
	Massillon, et al., "Identification of the Glycogenic Compound 5-Iodotubercidin as a General Protein Kinase Inhibitor", <i>Biochem J.</i> 299 : 123-128, 1994.						

Form PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket: 2004993-0011 (VPI/03-101 US)	In re Application No. 10/798,766
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				Applicant: Maltais <i>et al.</i>	
				Filing Date: March 11, 2004	Group:
				Phiel, et al., "GSK-3 α Regulates Production of Alzheimer's Disease Amyloid- β Peptides", <i>Nature</i> , 423 : 435-439, 2003.	
				International Search Report issued for corresponding PCT application PCT/US2004/007540.	
EXAMINER				DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

3788917